منابع مشابه
Fingolimod-associated macular oedema.
Jasani KM, et al. BMJ Case Rep 2017. doi:10.1136/bcr-2016-218912 Description A 54-year-old female with history of relapsing remitting multiple sclerosis (MS) was switched from interferon beta-1A (Avonex, Biogen) to fingolimod (Gilenya, Novartis) therapy after having two clinical relapses within 2 years while on treatment. As part of her treatment protocol, she was referred to the local ophthalm...
متن کاملFingolimod. Mitsubishi Pharma/Novartis.
Mitsubishi Pharma Corp and Novartis AG are developing fingolimod, an orally active immunosuppressant affecting lymphocyte re-circulation, for the potential prevention of transplant rejection and the treatment of autoimmune diseases, including multiple sclerosis. Fingolimodis a synthetic sphingosine analog that becomes phosphorylated in vivo and acts as a sphingosine-1-phosphate receptor agonist.
متن کاملFingolimod and multiple sclerosis
Neurology 2012;79:1942–1943 Unexpected consequences arise from our incomplete knowledge of the immune system. Who, for example, would have predicted that natalizumab, a monoclonal antibody targeting 4 integrin on leukocytes, would dramatically increase the risk of developing progressive multifocal leukoencephalopathy without causing notable immunosuppression? Thus, any new immunomodulatory ther...
متن کاملFingolimod therapy for multiple sclerosis.
Because of its potent efficacy and oral route of administration, the approval of fingolimod as treatment for relapsing-remitting multiple sclerosis (MS) was highly anticipated. The therapeutic and adverse effects are mediated by modulation of sphingosine 1-phosphate receptors. Fingolimod inhibits the egress of lymphocytes from lymph nodes and may also have direct effects on the central nervous ...
متن کاملDetermination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
The safety profile of fingolimod 0.5 mg, approved therapy for relapsing multiple sclerosis, is well established in clinical and real-world studies. As fingolimod is teratogenic in rats, it was considered important to assess the concentrations of fingolimod and its active metabolite, fingolimod-phosphate, in the semen of male patients on treatment and the risk of harming a fetus in a pregnant pa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Reactions Weekly
سال: 2021
ISSN: ['1179-2051', '0114-9954']
DOI: https://doi.org/10.1007/s40278-021-06123-0